PHOENIX, Ariz., Sept. 20, 2021 (GLOBE NEWSWIRE) — The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer in the world, and SonALAsense, a pioneer in developing non-invasive sonodynamic therapy (SDT) for managing fatal cancers so patients can become survivors, today announced positive initial results of the first-in-human Phase 0/1 clinical trial of SDT in recurrent glioblastoma patients. The initial results indicate SDT rapidly leads to targeted oxidative stress and cell death in human glioblastoma tissue. SDT was well-tolerated in all patients.

Read more here.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://blog.ourcrowd.com/aetna-the-first-national-insurer-to-cover-mr-imaging-guided-treatment-for-essential-tremor-2/